AU2021390552A1 - Peptide receptor radionuclide therapy - Google Patents

Peptide receptor radionuclide therapy Download PDF

Info

Publication number
AU2021390552A1
AU2021390552A1 AU2021390552A AU2021390552A AU2021390552A1 AU 2021390552 A1 AU2021390552 A1 AU 2021390552A1 AU 2021390552 A AU2021390552 A AU 2021390552A AU 2021390552 A AU2021390552 A AU 2021390552A AU 2021390552 A1 AU2021390552 A1 AU 2021390552A1
Authority
AU
Australia
Prior art keywords
conjugate
peptide
peg
peg moiety
mci
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2021390552A
Other languages
English (en)
Other versions
AU2021390552A9 (en
Inventor
Julie L. SUTCLIFFE
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of California San Diego UCSD
Original Assignee
University of California Berkeley
University of California San Diego UCSD
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of California Berkeley, University of California San Diego UCSD filed Critical University of California Berkeley
Publication of AU2021390552A1 publication Critical patent/AU2021390552A1/en
Publication of AU2021390552A9 publication Critical patent/AU2021390552A9/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/088—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0497—Organic compounds conjugates with a carrier being an organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/06—Macromolecular compounds, carriers being organic macromolecular compounds, i.e. organic oligomeric, polymeric, dendrimeric molecules
    • A61K51/065—Macromolecular compounds, carriers being organic macromolecular compounds, i.e. organic oligomeric, polymeric, dendrimeric molecules conjugates with carriers being macromolecules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/082—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins the peptide being a RGD-containing peptide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2021390552A 2020-12-04 2021-12-03 Peptide receptor radionuclide therapy Pending AU2021390552A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063121762P 2020-12-04 2020-12-04
US63/121,762 2020-12-04
PCT/US2021/061886 WO2022120226A1 (en) 2020-12-04 2021-12-03 Peptide receptor radionuclide therapy

Publications (2)

Publication Number Publication Date
AU2021390552A1 true AU2021390552A1 (en) 2023-06-29
AU2021390552A9 AU2021390552A9 (en) 2024-06-20

Family

ID=81853616

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2021390552A Pending AU2021390552A1 (en) 2020-12-04 2021-12-03 Peptide receptor radionuclide therapy

Country Status (9)

Country Link
US (1) US20240131206A1 (https=)
EP (1) EP4255891A4 (https=)
JP (1) JP2023552383A (https=)
KR (1) KR20230117581A (https=)
CN (1) CN116829541A (https=)
AU (1) AU2021390552A1 (https=)
CA (1) CA3203175A1 (https=)
MX (1) MX2023006483A (https=)
WO (1) WO2022120226A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025160502A1 (en) 2024-01-26 2025-07-31 The Regents Of The University Of California Peptide receptor radionuclide therapy

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0282057A3 (en) * 1987-03-11 1990-03-07 The Board Of Regents Of The University Of Michigan Chemo-radio-immuno-conjugates
MX340566B (es) * 2007-03-27 2016-07-14 Radiomedix Inc Composiciones para formacion de imagen objetivo y terapia.
US20120015899A1 (en) * 2008-10-25 2012-01-19 Plant Bioscience, Limited Modified plant virus particles and uses therefor
WO2011082191A1 (en) * 2009-12-30 2011-07-07 Ge Healthcare Limited Method of using a 99mtc-labelled injection rgd compound and a [18f]-labelled rgd injection compound in external beam radiotherapy planning
CA2945945C (en) * 2014-04-15 2023-10-03 The Regents Of The University Of California Bi-terminal pegylated integrin-binding peptides and methods of use thereof
EP3468984A4 (en) * 2016-06-13 2020-03-11 The Regents of the University of California ALPHA (V) BETA (6) BINDING PEPTIDES AND METHODS OF USE THEREOF
MX2019005742A (es) * 2016-11-23 2019-09-13 Cancer Targeted Tech Llc Inhibidores de antigeno de membrana especifico de la prostata (psma) de union a albumina.
GB201706472D0 (en) * 2017-04-24 2017-06-07 Cancer Res Tech Ltd Tumour-targeting peptide variants
CN111032632B (zh) * 2017-05-30 2024-04-12 约翰霍普金斯大学 用于前列腺癌的腔内放射疗法的前列腺特异性膜抗原靶向的高亲和力剂
CN109091683B (zh) * 2018-08-10 2019-10-18 北京大学 一种用于整合素αvβ6靶向的环状多肽放射性药物及其制备方法
WO2021226432A2 (en) * 2020-05-08 2021-11-11 The Regents Of The University Of California Methods of detecting and treating lung damage in respiratory-related viral infections

Also Published As

Publication number Publication date
WO2022120226A1 (en) 2022-06-09
CN116829541A (zh) 2023-09-29
EP4255891A4 (en) 2026-03-18
AU2021390552A9 (en) 2024-06-20
CA3203175A1 (en) 2022-06-09
US20240131206A1 (en) 2024-04-25
JP2023552383A (ja) 2023-12-15
EP4255891A1 (en) 2023-10-11
KR20230117581A (ko) 2023-08-08
MX2023006483A (es) 2023-07-20

Similar Documents

Publication Publication Date Title
Chen et al. Integrin αβ3-targeted imaging of lung cancer
JP6997135B2 (ja) Ｇｒｐｒ陽性ガンの検出、診断及び治療のためのｇｒｐｒアンタゴニスト
EP3766893B1 (en) 177lu-dota-hynic-ipsma as a therapeutic radiopharmaceutical targeting prostate-specific membrane antigen
US12605447B2 (en) Stable formulations for radionuclide complexes
US8986651B2 (en) Compounds with reduced ring size for use in diagnosing and treating melanoma, including metastatic melanoma and methods related to same
KR102934560B1 (ko) 신장 보호 물질로서의 파라-아미노히푸르산(pah)
KR20190094160A (ko) 방사선 요법 및 진단 영상용 제형
WO2011005380A2 (en) Arg-gly-asp-conjugated alpha-melanocyte stimulating hormone hybrid peptide for use in diagnosing and treating melanoma, including metastatic melanoma and methods related to same
Chen et al. In vivo examination of 188Re (I)-tricarbonyl-labeled trastuzumab to target HER2-overexpressing breast cancer
US20240131206A1 (en) Peptide receptor radionuclide therapy
Prasanphanich et al. The effects of linking substituents on the in vivo behavior of site-directed, peptide-based, diagnostic radiopharmaceuticals
US20240342322A1 (en) Netrin-1 detection, companion test and therapy based on radiations
JP2024500829A (ja) 治療診断剤として使用するための放射性標識α－Ｖβ－３及び／又はα－Ｖβ－５インテグリンアンタゴニスト
HK40103039A (zh) 肽受体放射性核素治疗
WO2025160502A1 (en) Peptide receptor radionuclide therapy
Ahmad The Use of Bioorthogonal Chemistry to Create 99mTc and Micelle-based Diagnostic Agents
WO2024206972A1 (en) Compounds and combinations for diagnosing and treating melanoma and methods related to the same
WO2026083399A1 (en) Conjugates and use of same for theranostics
Däpp PEGylation: a strategy to improve the diagnosis and therapy relevant pharmacokinetic properties of bombesin analogues for targeting GRP receptor-positive tumours
JP2015083546A (ja) 癌の原発巣・骨転移の検査・治療用放射性標識薬剤

Legal Events

Date Code Title Description
SREP Specification republished